Recce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestones

Recce Pharmaceuticals received an A$3.67 million income tax refund, strengthening its balance sheet. The update is likely supportive for near-term liquidity but appears incremental rather than transformative.

Analysis

Recce Pharmaceuticals received an A$3.67 million income tax refund, strengthening its balance sheet. The update is likely supportive for near-term liquidity but appears incremental rather than transformative.